An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if Aranesp® administered once every 4 weeks to chronic
kidney disease subjects is safe and efficacious in maintaining haemoglobin levels greater
than or equal to 100 g/L.